tiprankstipranks
Editas Medicine Inc (GB:0IFK)
LSE:0IFK
UK Market
0IFK
Editas Medicine
RESEARCH TOOLSreports

Editas Medicine (0IFK) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0IFK Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
1 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Editas
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0IFK Stock 12 Month Forecast

Average Price Target

$5.75
▲(88.52% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $5.75 with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 88.52% change from the last price of $3.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","9":"$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.11,3.486153846153846,3.8623076923076924,4.2384615384615385,4.614615384615385,4.990769230769231,5.366923076923078,5.743076923076924,6.11923076923077,6.495384615384616,6.871538461538462,7.247692307692308,7.623846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.11,3.313076923076923,3.516153846153846,3.7192307692307693,3.922307692307692,4.125384615384616,4.328461538461538,4.531538461538462,4.734615384615385,4.937692307692307,5.140769230769231,5.343846153846155,5.546923076923077,{"y":5.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.11,3.1784615384615384,3.246923076923077,3.315384615384615,3.3838461538461537,3.4523076923076923,3.520769230769231,3.5892307692307694,3.6576923076923076,3.726153846153846,3.7946153846153847,3.863076923076923,3.9315384615384614,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.539,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.155,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.209,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.185,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.635,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.469,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$5.75Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on GB:0IFK
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$6
Buy
96.72%
Upside
Initiated
08/18/26
Editas Medicine initiated with a Buy at LadenburgEditas Medicine initiated with a Buy at Ladenburg
Bank of America Securities Analyst forecast on GB:0IFK
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
H.C. Wainwright Analyst forecast on GB:0IFK
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$3→$5
Buy
63.93%
Upside
Reiterated
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
JonesTrading Analyst forecast on GB:0IFK
Boris Peaker
JonesTrading
JonesTrading
$8
Buy
162.30%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on GB:0IFK
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
RBC Capital Analyst forecast on GB:0IFK
Luca Issi
RBC Capital
RBC Capital
$4
Hold
31.15%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Evercore ISI Analyst forecast on GB:0IFK
Jonathan Miller
Evercore ISI
Evercore ISI
$15
Buy
391.80%
Upside
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
Chardan Capital Analyst forecast on GB:0IFK
Geulah Livshits
Chardan Capital
Chardan Capital
$4
Buy
31.15%
Upside
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
Truist Financial Analyst forecast on GB:0IFK
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on GB:0IFK
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on GB:0IFK
Yanan Zhu
Wells Fargo
Wells Fargo
$4
Hold
31.15%
Upside
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on GB:0IFK
William Maughan
Clear Street
Clear Street
$4.6
Buy
50.82%
Upside
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on GB:0IFK
Gena Wang
Barclays
Barclays
$3
Hold
-1.64%
Downside
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Ladenburg Thalmann & Co. Analyst forecast on GB:0IFK
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$6
Buy
96.72%
Upside
Initiated
08/18/26
Editas Medicine initiated with a Buy at LadenburgEditas Medicine initiated with a Buy at Ladenburg
Bank of America Securities Analyst forecast on GB:0IFK
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
H.C. Wainwright Analyst forecast on GB:0IFK
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$3→$5
Buy
63.93%
Upside
Reiterated
08/06/26
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
JonesTrading Analyst forecast on GB:0IFK
Boris Peaker
JonesTrading
JonesTrading
$8
Buy
162.30%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on GB:0IFK
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
RBC Capital Analyst forecast on GB:0IFK
Luca Issi
RBC Capital
RBC Capital
$4
Hold
31.15%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Zimmer Biomet Holdings (NYSE: ZBH) and Editas Medicine (NASDAQ: EDIT)
Evercore ISI Analyst forecast on GB:0IFK
Jonathan Miller
Evercore ISI
Evercore ISI
$15
Buy
391.80%
Upside
Reiterated
05/27/26
Editas Medicine preclinical data 'looks highly supportive,' says Evercore ISIEditas Medicine preclinical data 'looks highly supportive,' says Evercore ISI
Chardan Capital Analyst forecast on GB:0IFK
Geulah Livshits
Chardan Capital
Chardan Capital
$4
Buy
31.15%
Upside
Reiterated
05/05/26
Editas Medicine price target raised to $4 from $3.50 at ChardanEditas Medicine price target raised to $4 from $3.50 at Chardan
Truist Financial Analyst forecast on GB:0IFK
Joon Lee
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), DocGo (NASDAQ: DCGO) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan Analyst forecast on GB:0IFK
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT) and Ascend Wellness Holdings LLC (Other OTC: AAWH)
Wells Fargo Analyst forecast on GB:0IFK
Yanan Zhu
Wells Fargo
Wells Fargo
$4
Hold
31.15%
Upside
Reiterated
03/10/26
Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)
Clear Street Analyst forecast on GB:0IFK
William Maughan
Clear Street
Clear Street
$4.6
Buy
50.82%
Upside
Reiterated
03/10/26
Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)
Barclays Analyst forecast on GB:0IFK
Gena Wang
Barclays
Barclays
$3
Hold
-1.64%
Downside
Reiterated
11/11/25
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Editas Medicine

3 Months
Phil NadeauTD Cowen
Success Rate
8/15 ratings generated profit
53%
Average Return
-2.32%
Copying Phil Nadeau's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -2.32% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
11/15 ratings generated profit
73%
Average Return
+17.65%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +17.65% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
11/15 ratings generated profit
73%
Average Return
+25.85%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 73.33% of your transactions generating a profit, with an average return of +25.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0IFK Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
8
6
4
3
3
Buy
3
2
2
1
1
Hold
4
1
1
1
1
Sell
2
1
1
1
1
Strong Sell
0
0
0
0
0
total
17
10
8
6
6
In the current month, 0IFK has received 4 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 0IFK average Analyst price target in the past 3 months is 5.75.
Each month's total comprises the sum of three months' worth of ratings.

0IFK Financial Forecast

0IFK Earnings Forecast

Next quarter’s earnings estimate for 0IFK is -$0.19 with a range of -$0.25 to -$0.13. The previous quarter’s EPS was -$0.15. 0IFK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0IFK has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0IFK is -$0.19 with a range of -$0.25 to -$0.13. The previous quarter’s EPS was -$0.15. 0IFK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0IFK has Performed in-line its overall industry.

0IFK Sales Forecast

Next quarter’s sales forecast for 0IFK is $4.49M with a range of $500.00K to $12.01M. The previous quarter’s sales results were $11.89M. 0IFK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0IFK has Performed in-line its overall industry.
Next quarter’s sales forecast for 0IFK is $4.49M with a range of $500.00K to $12.01M. The previous quarter’s sales results were $11.89M. 0IFK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0IFK has Performed in-line its overall industry.

0IFK Stock Forecast FAQ

What is GB:0IFK’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is 5.75.
    What is GB:0IFK’s upside potential, based on the analysts’ average price target?
    Editas Medicine Inc has 88.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Editas Medicine Inc a Buy, Sell or Hold?
          Editas Medicine Inc has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Editas Medicine Inc’s share price target?
            The average share price target for Editas Medicine Inc is 5.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $8.00 ,and the lowest forecast is $4.00. The average share price target represents 88.52% Increase from the current price of $3.05.
              What do analysts say about Editas Medicine Inc?
              Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Editas Medicine Inc?
                To buy shares of GB:0IFK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.